September 28, 10:00 EST In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid [...]
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]
Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its REpAb® antibody discovery platform was used to successfully sequence a complex mixture of functional antibodies directly from the serum of a human patient after receiving a COVID-19 vaccine. “This demonstrates a significant breakthrough in antibody discovery technology [...]
In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]
In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]
In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of Next Generation Protein Sequencing, SPR, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based [...]
Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM™ assay as a Laboratory Developed Test (LDT). EasyM™ [...]
Bruker Launches de novo Sequencing for Immunopeptidomics, Library-Free dia-PASEF, Mass Dynamics Knowledge Visualization At the 19th US HUPO, Bruker Corporation (Nasdaq: BRKR) announced important bioinformatics launches for 4D-Proteomics on the timsTOF platform: A novel de novo sequencing algorithm was developed in collaboration with Rapid Novor Inc., using over 1.7 million PASEF data-points to improve accuracy and speed for immunopeptidomics [...]
In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]
In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly [...]
Webinar Highlights You will learn: Introduction to the structure and function of the tuberous sclerosis protein complex (pTSC) A novel strategy for isolating and purifying protein complexes from native sources using recombinantly produced Fabs How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid design and engineering of recombinant antibody [...]
Alpaca Serum Antibodies Decoded with Rapid Novor’s De Novo Protein Sequencing Technology Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, announced today that its REpAb® antibody discovery platform was used to successfully sequence 10 unique nanobodies directly from an alpaca’s serum polyclonal antibody proteins. Furthermore, the 10 nanobodies were recombinantly [...]
As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.
Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Research Challenges in Veterinary Medicine Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Non-invasive, sensitive, accurate, and easy-to-manufacture IVDs will be critical to detect and monitor diseases where misfolded proteins play a significant role such as neurological illnesses like Alzheimer’s, cancers like multiple myeloma, among others.
There have been cases where researchers have trusted a kit, and they see a positive reaction only to, unfortunately, realize that the kit was actually detecting another protein because the kit’s antibody lot changed. Such was the case for the University of Toronto’s Diamandis team who spent half a million dollars and nearly two years due to an unreliable antibody. A certificate proving that the protein sequence of an antibody remains unchanged would have easily avoided the aforementioned mishaps.
Polyclonal antibodies are popular research reagents for their high sensitivity and robust cross-platform performance. But few companies consider them viable for therapeutic applications as they are almost impossible to characterize. Additionally, they suffer from a lack of reproducibility and limited supply. Monoclonal antibodies (mAbs) can be reliably characterized and produced for therapeutic applications, but are more costly to discover and develop. Rapid Novor’s REpAb technology can overcome these limitations by capturing the sequences of the most abundant IgG in a pAb and enabling indefinite antibody production. Here we report the first successful conversion of a goat polyclonal antibody into a cocktail of recombinant mAbs using only the pAb protein sample.
Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.
Amino acids are small organic molecules that make up peptides and proteins. All living organisms share the same set of amino acids. Amino acids come together in different orders (sequences) to form proteins. As such, each type of protein has a different three-dimensional structure and biological activity.
Our team, along with four other industry panelists, discuss ways to safeguard their research through recombinant antibodies, cell culturing procedures, antibody protein sequences, and reference identifiers.
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
Protein sequencing is a method that typically utilizes mass spectrometry (MS) to determine the amino acid code of a protein1. Prior to the development of mass spectrometry, Edman degradation, a method involving the stepwise degradation of peptides to derive the order of amino acids, was the mainstream approach. Nowadays, mass spectrometry is favored due to its ease of use and high throughput capabilities, though Edman degradation is still employed for specific applications in which the technique is well suited.
Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases
Amino acids (aa)—the building blocks of proteins—are simple molecules characterized by a variable R group flanked either side by an amino group and a carboxyl group. With around 20 different commonly found amino acids, each one can bond with another to produce chains that can be classified as peptides (typically below 50 aa) and proteins (sequences above 50 aa)—molecules ubiquitous to every known organism.
Amino acid sequencing is commonly performed using Edman degradation or mass spectrometry (MS). While mass spectrometry is favoured for its high throughput capabilities and ease of use, both techniques possess their own features and limitations. This article summarizes some of the key pain points inherent in the two methodologies when determining the amino acid sequence.
Antibodies are used in a variety of ways in academia and industry, from tools to therapeutics. Because antibodies are produced using live processes, which are naturally error-prone, validation is required from time to time. Furthermore, to develop biological therapeutics, the protein sequence must be confirmed as part of the regulatory process.
DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease of use make it one of the most widely used technologies in life sciences.
As proteins are assembled, they fold into different structural orders: from primary to quaternary. The exact sequence of the primary structure (the amino acid sequence) will dictate how a protein will fold and function. The importance of the primary structure has been noted in several studies, where changes in the original amino acid sequence have resulted in affinity problems, binding disruption, reduced half-life, and higher aggregation odds.
Of interest to human and veterinary drug development scientists, biologics and biosimilars development scientists, scientists performing pre-clinical assay development, immunotherapy researchers, oncolytic therapy development scientists, gene therapy development scientists, gene therapy, and oncolytic therapy researchers, CAR-T, and CAR-NK development scientists
Proteins are composed of peptide chains, which in turn are made up of a string or linear sequence of amino acids. Every amino acid has a basic structure containing an amino (-NH2) group and a carboxylic (-COOH) group (Figure 1B). To form a peptide, amino acids link to each other via a peptide bond, which involves the reaction between the carboxylic group of one amino acid and the amine group of another amino acid.
This webinar offers insight into how DNA and protein sequencing compare to each other.
Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, announced today that it has reached a major milestone in the life sciences industry by being the first to successfully sequence polyclonal antibodies directly from proteins without DNA sequencing data. The team [...]
Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®. After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.
Other than a paucity in widespread use, such efforts still do not address the main issue: the uniqueness of antibodies. Unlike currency, antibodies are non-fungible. To manufacture a replica of a specific antibody, we must first know its sequence. Sometimes, scientists may obtain the sequence through nucleotide sequencing means.
Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.
When it comes to polyclonal antibodies, how they are discovered can be just as important as how they are reproduced. In our talk originally presented at Antibody Engineering & Therapeutics Digital 2021, we highlighted the latest technology that’s capable of capturing the most abundant and high-affinity monoclonal antibodies directly from a poly mixture.
At PepTalk 2021, we discussed the importance of antibody standardization and explained why it’s crucial for the longevity of your research. You can listen to the full on-demand video here.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
If you could have guaranteed stability, certainty, and reproducibility for your research, would you be interested? Imagine this, if you’re 2 years into your project and your freezer died along with all of your important cell lines, what would you do? This is just one of the situations covered in this webinar, along with many other solutions researchers have begun to implement to safeguard their efforts. Whether you’re looking to proceed with stability and certainty or you’re looking for an immediate solution for your current reproducibility challenges, protein sequencing may be the answer.
Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.
Kitchener Biotech Rapid Novor Raised $5M USD to Decode Immune System Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, announced today that it has secured a $5 million US dollar Series A round of financing led by Co-Win Venture. The investment will accelerate the company’s growth in technological and clinical [...]
In this on-demand webinar, our scientific sales executive Jennifer, will briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies.
Next Generation Protein Sequencing Company Rapid Novor Enters into New Phase of Growth Rapid Novor, Inc., the world's leader in antibody protein sequencing using mass spectrometry, is pleased to announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home to four proteomics-grade mass spectrometers among other analytical instruments, the new [...]
In this on-demand webinar, we discuss why it is important to characterize antibodies based on their physical properties not just by what they bind, and how you can easily do the former via mass spectrometry-based protein sequencing.
Rapid Novor Inc Expands Their Proteomics Lab and Welcomes the 3rd Mass Spectrometer Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces the expansion of their mass spectrometry facility in Kitchener. With this expansion, the company tripled the laboratory footprints in order to host the newly installed Thermo Fisher [...]
Canadian Mass Spectrometry Veteran, Paul Taylor, Joins Rapid Novor Inc. Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces that the Canadian mass spectrometry veteran, Mr. Paul Taylor has joined the team as the Core Facility Manager. Prior to joining Rapid Novor, Mr. Taylor has been the Manager and [...]
Dr. Thierry Le Bihan Joins Rapid Novor Inc. to Further Advance Antibody Protein Sequencing Technologies Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces that Dr. Thierry Le Bihan has joined the team as a Senior Scientist. Prior to joining Rapid Novor, Dr. Le Bihan was a senior lecturer [...]
Rapid Novor Inc Announces Residency in JLABS @ Toronto Rapid Novor Inc, the world's leader in antibody protein sequencing using mass spectrometry, today announces that it becomes a resident company in Johnson & Johnson Innovation, JLABS @ Toronto, located in the MaRS Centre in Toronto, Canada. Rapid Novor Inc is a Kitchener-Waterloo based company dedicated [...]
Next-Generation Protein Sequencing – CEOCFO Magazine Interview with Rapid Novor Inc KITCHENER, Ontario, Aug. 22, 2017 /PRNewswire-iReach/ -- Rapid Novor Inc, the world leader in the next-generation protein sequencing, today announces that Mingjie Xie, the CEO of Rapid Novor Inc, has been interviewed by CEOCFO Magazine's Senior Editor Lynn Fosse. The interview, included in the [...]
Rapid Novor Opens Research Lab In Kitchener To Develop The Next-Generation Protein Sequencing Technology KITCHENER, Ontario, July 19, 2017 /PRNewswire-iReach/ -- Rapid Novor Inc, the world leader in next-generation protein sequencing, today announces that after six months of planning, setup and testing, its first proteomics grade mass spectrometry lab is now fully in operation. This [...]